Virtus Investment Advisers LLC Acquires 22,348 Shares of Novavax, Inc. $NVAX

Virtus Investment Advisers LLC boosted its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 56.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 62,153 shares of the biopharmaceutical company’s stock after purchasing an additional 22,348 shares during the period. Virtus Investment Advisers LLC’s holdings in Novavax were worth $392,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in NVAX. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Novavax in the 1st quarter worth approximately $99,000. Federated Hermes Inc. lifted its holdings in shares of Novavax by 11.1% during the first quarter. Federated Hermes Inc. now owns 56,124 shares of the biopharmaceutical company’s stock valued at $360,000 after acquiring an additional 5,618 shares during the period. XTX Topco Ltd acquired a new stake in shares of Novavax in the 1st quarter valued at $435,000. Jupiter Asset Management Ltd. bought a new stake in shares of Novavax in the 1st quarter worth about $1,907,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Novavax by 9.1% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 33,169 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 2,780 shares in the last quarter. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Price Performance

Novavax stock opened at $7.02 on Friday. The company has a current ratio of 2.36, a quick ratio of 2.34 and a debt-to-equity ratio of 5.93. The firm has a market capitalization of $1.14 billion, a P/E ratio of 3.08, a PEG ratio of 0.12 and a beta of 2.68. The business has a 50-day moving average of $8.03 and a 200-day moving average of $7.61. Novavax, Inc. has a 1 year low of $5.01 and a 1 year high of $11.55.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.17). Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The firm had revenue of $70.45 million for the quarter, compared to analyst estimates of $55.63 million. During the same quarter in the prior year, the firm posted ($0.76) EPS. The firm’s revenue for the quarter was down 16.7% compared to the same quarter last year. Novavax has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Novavax, Inc. will post -1.46 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on NVAX. JPMorgan Chase & Co. reduced their target price on Novavax from $7.00 to $6.00 and set an “underweight” rating on the stock in a report on Tuesday, November 18th. Bank of America reiterated an “underperform” rating and issued a $7.00 price objective (down previously from $9.00) on shares of Novavax in a research report on Wednesday, August 20th. Wall Street Zen cut Novavax from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. TD Cowen lowered their target price on Novavax from $8.00 to $7.00 and set a “hold” rating for the company in a research note on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Novavax in a research note on Tuesday. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $11.25.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.